Today’s Featured Stock
Valued at $2.95 billion, SELLAS Life Sciences (SLS) focuses on the development of novel cancer immunotherapies for various cancer indications.
What I’m Watching
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction, a Weighted Alpha above 50+, and a 60-month beta above 1.5. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. SLS checks those boxes. The Trend Seeker issued a new “Buy” signal on May 13. Since then, the stock has gained 119.20%.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
www.barchart.comBarchart’s Technical Indicators for SELLAS Life Sciences
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
SELLAS scored a 5-year high of $15.88 on June 30.
SELLAS has a Weighted Alpha of +367.22. SLS has a 100% “Buy” opinion from Barchart. The stock has gained 559.90% over the past 52 weeks. SELLAS has its Trend Seeker “Buy” signal intact. The stock recently traded at $14.16 with a 50-day moving average of $7.98. SLS has made 8 new highs and gained 74% over the past month. 60-month beta of 2.42. Relative Strength Index (RSI) is at 67.95. There’s a technical support level around $13.60.Don’t Forget the Fundamentals
$2.95 billion market capitalization. This company currently has no revenue and is in the drug development and trial stages.Analyst and Investor Sentiment on SELLAS Life Sciences
The Wall Street analyst followed by Barchart gives the stock 1 “Strong Buy” opinion. Value Line rates the stock “Highest” but that is based solely on price performance. CFRA’s MarketScope rates the stock a “Hold.” Morningstar thinks the stock is 39% overvalued with a fair value of $10.95. 36,940 investors are following the stock on Seeking Alpha, which rates it a “Hold.” Their analysts note a high valuation and a lack of revenue and earnings. Short interest is a high 32.22% of the float with 9.25 days to cover the float.The Bottom Line on SELLAS Life Sciences
This stock is totally speculative. Although it has positive price momentum and a large following, the number of short sellers is growing. The stock is a coin flip.
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Oklo Stock Just Got a Major Win. 2026 Could Still Be Its Breakout Year. Mark Cuban Asks What If You Didn’t Need Health Insurance — And Hospitals Just Treated You, Then Took 10% of Your Pay? Analysts Say This Stock Is a Buy Now to Take Advantage of a Historic AI Supercycle Only 3 Under-the-Radar Dividend Stocks Survived This Brutal Screen. One Could Rally 115%.